Puma Biotechnology, Inc. (PBYI) was a big mover last session, as its shares surged nearly 12% on the day. The surge came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the medical stock as it is now up roughly 127% in the past one-month time frame.
In the last 30-day time frame, the company has seen three negative estimate revisions and its Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if Friday’s move higher lasts.
Puma Biotechnology currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Some better-ranked medical stocks include Lannett Company, Inc. (LCI), Jazz Pharmaceuticals Plc (JAZZ) and Questcor Pharmaceuticals, Inc. (QCOR). All three companies carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
PUMA BIOTECHNOLOGY INC (PBYI): Free Stock Analysis Report
LANNETT CO INC (LCI): Free Stock Analysis Report
JAZZ PHARMACEUTICALS PLC IRELAND (JAZZ): Free Stock Analysis Report
QUESTCOR PHARMACEUTICALS INC (QCOR): Free Stock Analysis Report
Zacks Investment Research
- Health Care Industry
- Finance Trading